Finally, we combined metabolomics and network pharmacology analyses to identify the key targets of IPE for RA as ALB and AKT1, with endogenous biomarkers being D-mannose and cytosine, and the key signaling pathways involved are SLC-mediated transmembrane transport and C-type lectin receptor signaling pathway. The gene discussed is CCL21; the disease is rheumatoid arthritis.